Clinical Trial

Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To study the safety and effectiveness of oncolytic Vaccinia VIrus-Delivered Targeted CD19 In Vivo CAR-T/M Therapy for Refractory/Relapsed B-Cell Lymphoma
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07398963
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Refractory/Relapsed B-cell Lymphoma
Enrollment 48 participants
Start Date 2026-02
Primary Completion 2029-07 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-10